Table 4.
Univariate and multivariate analyses for overall survival.
| Variables | Univariate | Multivariate | |
|---|---|---|---|
| p | Hazard Ratio (95%CI) | p | |
| Patient characteristics | |||
| Age | <0.01 * | 1.04 (1.03–1.05) | <0.01 * |
| Female (vs. male) | <0.01 * | 0.82 (0.62–1.09) | 0.16 |
| Pack-year | <0.01 * | 1.04 (1.03–1.05) | 0.14 |
| Carcinoembryonic antigen | |||
| Value | 0.58 | ||
| Clinical N stage | |||
| N0 (vs. cN1-2) | <0.01 * | 0.53 (0.36–0.79) | 0.07 |
| Histology | |||
| Adenocarcinoma or SQCC | <0.01 * | 0.48 | |
| Procedures | |||
| More than lobectomy | <0.01 * | 0.92 (0.58–1.48) | 0.74 |
| Approach | |||
| Thoracotomy (vs. Thoracoscopy) | <0.01 * | 1.56 (1.03–2.37) | 0.04 * |
| Lymph node dissection | |||
| L-SND (vs. SND) | <0.01 | 0.78 (0.61–0.99) | 0.04 * |
| Adjuvant | |||
| Chemotherapy and/or radiotherapy (vs. No) |
0.37 | ||
| Pathological stage | |||
| More advanced | <0.01 * | 1.32 (1.22–1.43) | <0.01 * |
| Mutation status | |||
| EGFR or ALK positive (vs. negative) | <0.01 * | 1.20 (0.90–1.60) | 0.22 |
SQCC, squamous cell carcinoma; L-SND, lobe-specific nodal dissection; SND, systemic nodal dissection; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; CI, confidence interval. p < 0.05, significant *.